Drug Combination Details
| General Information of the Combination (ID: C94307) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | PD173074 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | c-RAF | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Phosphorylation | ERK1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | FGFR1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | SRC | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | SK-MES-1 | CVCL_0630 | Lung squamous cell carcinoma | Homo sapiens | ||
| SW900 | CVCL_1731 | Lung squamous cell carcinoma | Homo sapiens | |||
| NCI-H2170 | CVCL_1535 | Lung squamous cell carcinoma | Homo sapiens | |||
| In-vivo Model | The SK-MES-1 xenograft model was developed by subcutaneous injection of 1*107 cells with Matrigel into the upper back of 40 nude mice (female, 4-6-week-old, 10-14 g, BALB/cAnN-nu). | |||||
| Experimental
Result(s) |
Combined ATO/PD173074 reduced cell viability along with increased sub-G1 population, phosphatidylserine externalization and mitochondrial membrane depolarization more significantly than single treatments. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Combination effects of arsenic trioxide and fibroblast growth factor receptor inhibitor in squamous cell lung carcinoma. Lung Cancer. 2016 Nov;101:111-119. | |||
